DNA-FISH Probes
Fluorescent in situ hybridization (FISH) is a sensitive and accurate technique that allows the detection of chromosome aberrations. In this method, a single-stranded fluorescent-labeled nucleic acid sequence (probe) complementary to a target genomic sequence is hybridized to metaphase chromosomes and interphase nuclei to detect the presence and absence of a given abnormality. FISH complements traditional cytogenetic karyotype analysis. The chief advantage of FISH is that is can be applied to non-dividing cells and a variety of specimen types. FISH is a method of choice for diagnosis, prognosis, treatment response, and minimal residual disease detection in hematopoietic neoplasms (leukemia, lymphomas, multiple myeloma, and myelodysplasia) and solid tumors (breast cancer, non-small cell lung cancer, colorectal cancer, and cervical cancer).
Supported by Small Business Innovation Research grants from the National Institute of Health and taking into account the most recent developments in research on genomic changes associated with cancer, CGI has designed and developed an innovative and reliable portfolio of DNA-FISH Probes. The range of genetic aberrations detected by the DNA-FISH Probes includes translocations (fusion and break-apart probes), deletions, gains, and amplifications. The unique nature of several of these DNA-FISH Probes is protected by intellectual property.
The DNA-FISH Probes are manufactured in Italy by Cancer Genetics Italia S.r.l. and are not commercially available in the US at this time. The DNA-FISH Probes are CE marked. Cancer Genetics Italia’s mission is to provide reagents of the highest sensitivity and specificity to the clinical community in the European Union and the rest of the world. For further information, please go to http://www.cancergeneticsitalia.com.
